Notably, FLG rs749682384 and IL6R rs2228145 variants emerged as predictors of favorable response to Dupilumab, while RPTN rs3001978 and TSLP rs2289276 variants were associated with a therapy failure.<h4>Conclusions</h4>This study identified genetic signatures in skin barrier and Th2 pathway genes associated with clinical phenotypes and differential responses to Dupilumab in AD. The gene discussed is TSLP; the disease is Alzheimer disease.